Search hospitals > California > San Francisco
San Francisco General Hospital
Claim this profileSan Francisco, California 94110
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for HIV/AIDS
Conducts research for AIDS
Conducts research for Breast Cancer
258 reported clinical trials
46 medical researchers
Summary
San Francisco General Hospital is a medical facility located in San Francisco, California. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, HIV/AIDS, AIDS, Breast Cancer and other specialties. San Francisco General Hospital is involved with conducting 258 clinical trials across 386 conditions. There are 46 research doctors associated with this hospital, such as Hope Rugo, MD, Steven J Deeks, MD, Lee-may Chen, MD, and Priscilla Hsue, MD.Area of expertise
1HIV Infection
Global LeaderStage IV
Stage III
CD4+ cell count positive
2Human Immunodeficiency Virus Infection
Global LeaderTop PIs
Hope Rugo, MDUniversity of California San Francisco5 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
19 reported clinical trials
45 drugs studied
Steven J Deeks, MDSan Francisco General Hospital4 years of reported clinical research
Studies Human Immunodeficiency Virus Infection
Studies HIV Infection
12 reported clinical trials
15 drugs studied
Lee-may Chen, MDUCSF Medical Center-Mission Bay4 years of reported clinical research
Studies Serous Cystadenocarcinoma
Studies Ovarian Cancer
6 reported clinical trials
11 drugs studied
Priscilla Hsue, MDUCSF/Zuckerberg San Francisco General Hospital7 years of reported clinical research
Studies HIV Infection
Studies Human Immunodeficiency Virus Infection
5 reported clinical trials
6 drugs studied
Clinical Trials running at San Francisco General Hospital
Breast Cancer
Stroke
Heart Failure
Cancer
Breast cancer
HIV/AIDS
Cardiovascular Disease
Anal Cancer
HIV Infection
Lung Cancer
Imlunestrant
for Early Breast Cancer
This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.
Recruiting2 awards Phase 36 criteria
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting2 awards Phase 340 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at San Francisco General Hospital?
San Francisco General Hospital is a medical facility located in San Francisco, California. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, HIV/AIDS, AIDS, Breast Cancer and other specialties. San Francisco General Hospital is involved with conducting 258 clinical trials across 386 conditions. There are 46 research doctors associated with this hospital, such as Hope Rugo, MD, Steven J Deeks, MD, Lee-may Chen, MD, and Priscilla Hsue, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.